{
  "id": "5e47681b35b8f0833c000006",
  "type": "factoid",
  "question": "What is the target of Inebilizumab?",
  "ideal_answer": "Inebilizumab is an anti-CD19 antibody with enhanced antibody-dependent cell-mediated cytotoxicity against B cells, is currently being evaluated in multiple sclerosis and neuromyelitis optica.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/30915717",
    "http://www.ncbi.nlm.nih.gov/pubmed/29512131",
    "http://www.ncbi.nlm.nih.gov/pubmed/29143550",
    "http://www.ncbi.nlm.nih.gov/pubmed/29956883",
    "http://www.ncbi.nlm.nih.gov/pubmed/28910968",
    "http://www.ncbi.nlm.nih.gov/pubmed/27886126",
    "http://www.ncbi.nlm.nih.gov/pubmed/29447988",
    "http://www.ncbi.nlm.nih.gov/pubmed/31495497"
  ],
  "snippets": [
    {
      "text": "CONTENT: Although CD19-targeted agents (blinatumomab or inebilizumab) are not associated with an increased risk of infection, they may cause IgG hypogammaglobulinaemia and neutropenia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29447988",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In this respect, several B cell-targeted therapies emerged, including anti-CD20 antibodies (rituximab, ocrelizumab, and ofatumumab), anti-CD19 antibody (inebilizumab), and agents targeting the BAFF/APRIL signaling pathway (atacicept, belimumab, and LY2127399). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29512131",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Patients with a high PC signature at baseline showed greater improvement in the MRSS (mean \u00b1 SD change 35 \u00b1 16%; P = 6.30 \u00d7 10-4 ) following anti-CD19 treatment with inebilizumab (MEDI-551) than did patients with a low PC signature at baseline (mean \u00b1 SD change 8 \u00b1 12%; P = 0.104).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29956883",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In NMO, though there have yet to be any approved monoclonal antibodies, rituximab, anti-complement C5 (eculizumab), anti-IL-6 receptor (tocilizumab), anti-CD19 (inebilizumab) and non-pathogenic anti-aquaporin 4 (aquaporumab) have been suggested to be effective, and some of these are now under clinical trials.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28910968",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29143550",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Inebilizumab (formerly MEDI-551) binds to and depletes CD19+ B cells.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29143550",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27886126",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Inebilizumab (MEDI-551), an anti-CD19 antibody with enhanced antibody-dependent cell-mediated cytotoxicity against B cells, is currently being evaluated in MS and neuromyelitis optica.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27886126",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We aimed to assess the efficacy and safety of inebilizumab, an anti-CD19, B cell-depleting antibody, in reducing the risk of attacks and disability in NMOSD.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31495497",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Inebilizumab (formerly MEDI-551) binds to and depletes CD19 + B cells.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29143550",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A multicenter phase I study of inebilizumab, a humanized anti-CD19 monoclonal antibody, in Japanese patients with relapsed or refractory B-cell lymphoma and multiple myeloma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30915717",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "CONTENT\n\nAlthough CD19-targeted agents (blinatumomab or inebilizumab) are not associated with an increased risk of infection, they may cause IgG hypogammaglobulinaemia and neutropenia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29447988",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In this respect, several B cell-targeted therapies emerged, including anti-CD20 antibodies (rituximab, ocrelizumab, and ofatumumab), anti-CD19 antibody (inebilizumab), and agents targeting the BAFF/APRIL signaling pathway (atacicept, belimumab, and LY2127399).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29512131",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In this respect , several B cell-targeted therapies emerged , including anti-CD20 antibodies ( rituximab , ocrelizumab , and ofatumumab) , anti-CD19 antibody ( inebilizumab) , and agents targeting the BAFF/APRIL signaling pathway ( atacicept , belimumab , and LY2127399) . ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29512131",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In NMO , though there have yet to be any approved monoclonal antibodies , rituximab , anti-complement C5 ( eculizumab) , anti-IL-6 receptor ( tocilizumab) , anti-CD19 ( inebilizumab ) and non-pathogenic anti-aquaporin 4 ( aquaporumab ) have been suggested to be effective , and some of these are now under clinical trials . ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28910968",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Safety and tolerability of inebilizumab ( MEDI-551) , an anti-CD19 monoclonal antibody , in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised , placebo-controlled , escalating intravenous and subcutaneous dose study .",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29143550",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "A multicenter phase I study of inebilizumab , a humanized anti-CD19 monoclonal antibody , in Japanese patients with relapsed or refractory B-cell lymphoma and multiple myeloma .",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30915717",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "We aimed to assess the efficacy and safety of inebilizumab , an anti-CD19 , B cell-depleting antibody , in reducing the risk of attacks and disability in NMOSD .",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31495497",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We aimed to assess the efficacy and safety of inebilizumab, an anti-CD19, B cell-depleting antibody, in reducing the risk of attacks and disability in NMOSD.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31495497",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Inebilizumab (formerly MEDI-551) binds to and depletes CD19+ B cells.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29143550",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "CD19"
}